Drug and Alcohol Testing

Drug and Alcohol Testing

December 03, 2018

A ‘Day with DISA’ was DISA Global Solution’s first marijuana symposium, which educated employers on the importance of implementing a drug testing program that’s custom to their companies’ needs. For the event, DISA invited a number of select industry experts to present sessions to further help employers with valuable drug testing insights.

Drug and Alcohol Testing

November 26, 2018

DISA welcomed several well-respected industry speakers to present at the first annual ‘Day with DISA’ drug testing conferencing and networking event. One of those speakers was Richard Clay, Vice President of National Accounts at Psychemedics Corporation. Because Psychemedics is DISA’s preferred hair testing vendor partner, we asked Richard to present some of their real workplace data and breakdown positivity rates for marijuana both pre- and post-MRO review.

Drug and Alcohol Testing

November 09, 2018

As a result of the 2018 mid-term elections, Michigan, Missouri, and Utah have all legalized some form of marijuana. It’s imperative that employers remain up-to-date on marijuana changes as they could impact their company drug testing policies and procedures. Every time a state changes a marijuana law, it increasingly becomes more difficult for employers to keep track of.

Drug and Alcohol Testing

November 05, 2018

At DISA’s ‘Day with DISA’ drug testing conference and networking event on October 29th, DISA helped educate employers on valuable drug testing insights that will help them further protect their company. Colin Woods, DISA’s Vice President of Sales and Marketing presented on the History of Drug Testing and our 2019 Owner Survey to bring awareness to the powerful impact drug testing has in the workplace.

Drug and Alcohol Testing

October 31, 2018

Effective January 1, 2019, the Federal Transit Administration (FTA) is increasing its annual random drug testing rate from 25% to 50%. This is the first increase in random testing rates since 2007 and a direct result of positivity rates increasing to 1.06% in 2017.

Drug and Alcohol Testing

September 25, 2018

In late June 2018, the Food and Drug Administration (FDA) approved Epidiolex for sale in the U.S. It is the first prescription drug derived from the marijuana plant. The drug is designed to treat seizures for two rare forms of epilepsy: Dravet Syndrome and Lennox-Gastaut Syndrome. “Fast-track” designation was given to the drug during its approval process because it was the first FDA approval of a drug for the treatment of patients with Dravet Syndrome.1 “Orphan drug” designation (special status given to a drug that treats a rare condition or disease) was also given to the drug for use as a treatment for both Dravet Syndrome and Lennox-Gastaut Syndrome.

Drug and Alcohol Testing

August 27, 2018

At a state and federal level, marijuana laws continue to change across the U.S., and employers are finding it more difficult to keep up with the legal ramifications for their employees. It’s important for employers to remain up-to-date on the various laws for each state, understand how it will impact their employment screening processes, and when it’s a dangerous policy, speak out to their state and federal offices.